Trial Search Results

Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals

This clinical trial studies how well positron emission tomography (PET)/computed tomography (CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with cancer. PET/CT and PET/MRI may determine which scanner is best for the patient's type of cancer and other types of cancers.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Drug: F-18 FDG
  • Drug: Ga-68-DOTA-TATE
  • Device: Positron Emission Tomography / Computed Tomography (PET/CT) Scan
  • Device: Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan

Phase:

Phase 2

Eligibility


INCLUSION CRITERIA

   - Cancer diagnosis

   - Capable of complying with study procedures

   - Able to remain still for duration of imaging procedure (approximately 90 minutes
   total)

   - Written informed consent

EXCLUSION CRITERIA

   - Pregnant or nursing

   - Metallic implants

   - Impaired renal function

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305